$200M investment to advance clinical programs for Ambrx

$200M investment to advance clinical programs for Ambrx

Source: 
MedCity News
snippet: 

The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.